{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:44:12Z","timestamp":1776087852487,"version":"3.50.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ataxia-telangiectasia (A-T) is a human autosomal recessive disease caused by mutations in the gene encoding ataxia-telangiectasia mutated (ATM). A-T is characterized by progressive cerebellar degeneration, variable immunodeficiency, and a high incidence of leukemia and lymphoma. Recurrent sino-pulmonary infections secondary to immunodeficiency and hematopoietic malignancies are major causes of morbidity and mortality in A-T patients. In mice, an introduced mutation in Atm leads to a phenotype that recapitulates many of the symptoms of A-T, including immune system abnormalities and susceptibility to malignancy. Here we show that the replacement of the bone marrow compartment in Atm knockout mice (Atm-\/-) using a clinically relevant, nonmyeloablative host-conditioning regimen can be used to overcome the immune deficiencies and prevent the malignancies observed in these mice. Therefore, bone marrow transplantation may prove to be of therapeutic benefit in A-T patients. (Blood. 2004;104:572-578)<\/jats:p>","DOI":"10.1182\/blood-2003-12-4226","type":"journal-article","created":{"date-parts":[[2004,3,30]],"date-time":"2004-03-30T01:13:04Z","timestamp":1080609184000},"page":"572-578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice"],"prefix":"10.1182","volume":"104","author":[{"given":"Jessamyn","family":"Bagley","sequence":"first","affiliation":[{"name":"From the Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School; and Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L.","family":"Cortes","sequence":"additional","affiliation":[{"name":"From the Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School; and Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xandra O.","family":"Breakefield","sequence":"additional","affiliation":[{"name":"From the Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School; and Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Iacomini","sequence":"additional","affiliation":[{"name":"From the Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School; and Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021223264465100_REF1","unstructured":"Swift M. Genetics and epidemiology of ataxia-telangiectasia. Kroc Found Ser.1985;19: 133-146."},{"key":"2020021223264465100_REF2","unstructured":"Swift M, Morrell D, Cromartie E, et al. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet.1986; 39: 573-583."},{"key":"2020021223264465100_REF3","doi-asserted-by":"crossref","unstructured":"Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol.1997;15: 177-202.","DOI":"10.1146\/annurev.immunol.15.1.177"},{"key":"2020021223264465100_REF4","unstructured":"Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst.1986;77: 89-92."},{"key":"2020021223264465100_REF5","doi-asserted-by":"crossref","unstructured":"Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol.1998;31: 491-497.","DOI":"10.1002\/(SICI)1096-911X(199812)31:6<491::AID-MPO5>3.0.CO;2-B"},{"key":"2020021223264465100_REF6","doi-asserted-by":"crossref","unstructured":"Abadir R, Hakami N. Ataxia telangiectasia with cancer: an indication for reduced radiotherapy and chemotherapy doses. Br J Radiol.1983;56: 343-345.","DOI":"10.1259\/0007-1285-56-665-343"},{"key":"2020021223264465100_REF7","doi-asserted-by":"crossref","unstructured":"Weyl BA, Rosenthal J, Dale J, et al. Ataxia telangiectasia and lymphoma: an indication for individualized chemotherapy dosing\u2014report of treatment in a highly inbred Arab family. Pediatr Hematol Oncol.1995;12: 163-169.","DOI":"10.3109\/08880019509029550"},{"key":"2020021223264465100_REF8","doi-asserted-by":"crossref","unstructured":"Borghesani PR, Alt FW, Bottaro A, et al. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc Natl Acad Sci U S A.2000;97: 3336-3341.","DOI":"10.1073\/pnas.97.7.3336"},{"key":"2020021223264465100_REF9","doi-asserted-by":"crossref","unstructured":"Barlow C, Hirotsune S, Paylor R, et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell.1996;86: 159-171.","DOI":"10.1016\/S0092-8674(00)80086-0"},{"key":"2020021223264465100_REF10","doi-asserted-by":"crossref","unstructured":"Xu Y, Ashley T, Brainerd EE, et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects and thymic lymphoma. Genes Dev.1996; 10: 2411-2422.","DOI":"10.1101\/gad.10.19.2411"},{"key":"2020021223264465100_REF11","doi-asserted-by":"crossref","unstructured":"Elson A, Wang Y, Daugherty CJ, et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci U S A.1996;93: 13084-13089.","DOI":"10.1073\/pnas.93.23.13084"},{"key":"2020021223264465100_REF12","doi-asserted-by":"crossref","unstructured":"Giovannetti A, Mazzetta F, Caprini E, et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood.2002;100: 4082-4089.","DOI":"10.1182\/blood-2002-03-0976"},{"key":"2020021223264465100_REF13","doi-asserted-by":"crossref","unstructured":"Schubert R, Reichenbach J, Zielen S. Deficiencies in CD4+ and CD8+ T cell subsets in ataxia telangiectasia. Clin Exp Immunol.2002;129: 125-132.","DOI":"10.1046\/j.1365-2249.2002.01830.x"},{"key":"2020021223264465100_REF14","doi-asserted-by":"crossref","unstructured":"Paganelli R, Scala E, Scarselli E, et al. Selective deficiency of CD4+\/CD45RA+ lymphocytes in patients with ataxia-telangiectasia. J Clin Immunol.1992;12: 84-91.","DOI":"10.1007\/BF00918137"},{"key":"2020021223264465100_REF15","doi-asserted-by":"crossref","unstructured":"Buckley RH. Primary cellular immunodeficiencies. J Allergy Clin Immunol.2002;109: 747-757.","DOI":"10.1067\/mai.2002.123617"},{"key":"2020021223264465100_REF16","unstructured":"Saha K, Chopra K. Primary immune disorders in children and their diagnosis. J Commun Dis.1984;16: 11-17."},{"key":"2020021223264465100_REF17","doi-asserted-by":"crossref","unstructured":"Micheli R, Pirovano S, Calandra G, et al. Low thymic output and reduced heterogeneity of alpha\/beta, but not gamma\/delta, T lymphocytes in infants with ataxia-telangiectasia. Neuropediatrics.2003;34: 165-167.","DOI":"10.1055\/s-2003-41280"},{"key":"2020021223264465100_REF18","doi-asserted-by":"crossref","unstructured":"Bagley J, Tian C, Sachs DH, Iacomini J. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood.2002;99: 4394-4399.","DOI":"10.1182\/blood.V99.12.4394"},{"key":"2020021223264465100_REF19","doi-asserted-by":"crossref","unstructured":"Dialynas DP, Quan ZS, Wall KA, et al. Characterization of the murine T cell surface molecule designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu 3\/T4 molecule. J Immunol.1984;131: 2445-2451.","DOI":"10.4049\/jimmunol.131.5.2445"},{"key":"2020021223264465100_REF20","doi-asserted-by":"crossref","unstructured":"Sarmiento M, Glasebrook AL, Fitch FW. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol.1980;125: 2665-2672.","DOI":"10.4049\/jimmunol.125.6.2665"},{"key":"2020021223264465100_REF21","doi-asserted-by":"crossref","unstructured":"Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras: immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med.1985;162: 231-244.","DOI":"10.1084\/jem.162.1.231"},{"key":"2020021223264465100_REF22","doi-asserted-by":"crossref","unstructured":"Bagley J, Tian C, Sachs DH, Iacomini J. T cells mediate resistance to genetically modified bone marrow in lethally irradiated recipients. Transplantation.2002;74: 1454-1460.","DOI":"10.1097\/00007890-200211270-00019"},{"key":"2020021223264465100_REF23","doi-asserted-by":"crossref","unstructured":"Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood.2001;98: 1601-1606.","DOI":"10.1182\/blood.V98.5.1601"},{"key":"2020021223264465100_REF24","doi-asserted-by":"crossref","unstructured":"Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood.1996;88: 1887-1894.","DOI":"10.1182\/blood.V88.5.1887.1887"},{"key":"2020021223264465100_REF25","doi-asserted-by":"crossref","unstructured":"Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood.2002; 99: 4592-4600.","DOI":"10.1182\/blood.V99.12.4592"},{"key":"2020021223264465100_REF26","doi-asserted-by":"crossref","unstructured":"Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med.2000;192: 557-564.","DOI":"10.1084\/jem.192.4.557"},{"key":"2020021223264465100_REF27","doi-asserted-by":"crossref","unstructured":"Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant.1999;5: 133-143.","DOI":"10.1053\/bbmt.1999.v5.pm10392959"},{"key":"2020021223264465100_REF28","doi-asserted-by":"crossref","unstructured":"Sykes M, Sheard MA, Sachs DH. Effects of T cell depletion in radiation bone marrow chimeras, II: requirement for allogeneic T cells in the reconstituting bone marrow inoculum for subsequent resistance to breaking of tolerance. J Exp Med.1988;168: 661-673.","DOI":"10.1084\/jem.168.2.661"},{"key":"2020021223264465100_REF29","doi-asserted-by":"crossref","unstructured":"Sykes M, Sheard M, Sachs DH. Effects of T cell depletion in radiation bone marrow chimeras, I: evidence for a donor cell population which increases allogeneic chimerism but which lacks the potential to produce GVHD. J Immunol.1988; 141: 2282-2288.","DOI":"10.4049\/jimmunol.141.7.2282"},{"key":"2020021223264465100_REF30","doi-asserted-by":"crossref","unstructured":"Thomas ED, Sanders JE, Flournoy N, et al. Marrow transplantation for patients with acute lymphoblastic leukemia: a long-term follow-up. Blood.1983;62: 1139-1141.","DOI":"10.1182\/blood.V62.5.1139.1139"},{"key":"2020021223264465100_REF31","doi-asserted-by":"crossref","unstructured":"Thomas ED, Buckner CD, Clift RA, et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med.1979;301: 597-599.","DOI":"10.1056\/NEJM197909133011109"},{"key":"2020021223264465100_REF32","doi-asserted-by":"crossref","unstructured":"Santos GW. Marrow transplantation in acute nonlymphocytic leukemia. Blood.1989;74: 901-908.","DOI":"10.1182\/blood.V74.3.901.901"},{"key":"2020021223264465100_REF33","unstructured":"Beutler E, Blume KG, Bross KJ, et al. Bone marrow transplantation as the treatment of choice for \u201cgood risk\u201d adult patients with acute leukemia. Trans Assoc Am Physicians.1979;92: 189-195."},{"key":"2020021223264465100_REF34","doi-asserted-by":"crossref","unstructured":"Spitzer TR, McAfee SL, Dey BR, et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation.2003;75: 1748-1751.","DOI":"10.1097\/01.TP.0000064211.23536.AD"},{"key":"2020021223264465100_REF35","doi-asserted-by":"crossref","unstructured":"Kim HJ, Park CY, Park YH, et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant.2003;31: 79-86.","DOI":"10.1038\/sj.bmt.1703786"},{"key":"2020021223264465100_REF36","doi-asserted-by":"crossref","unstructured":"Liao MJ, Van Dyke T. Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma. Genes Dev.1999;13: 1246-1250.","DOI":"10.1101\/gad.13.10.1246"},{"key":"2020021223264465100_REF37","doi-asserted-by":"crossref","unstructured":"Petiniot LK, Weaver Z, Barlow C, et al. Recombinase-activating gene (RAG) 2-mediated V(D)J recombination is not essential for tumorigenesis in atm-deficient mice. Proc Natl Acad Sci U S A.2000;97: 6664-6669.","DOI":"10.1073\/pnas.97.12.6664"},{"key":"2020021223264465100_REF38","doi-asserted-by":"crossref","unstructured":"Petiniot LK, Weaver Z, Vacchio M, et al. RAG-mediated V(D)J recombination is not essential for tumorigenesis in Atm-deficient mice. Mol Cell Biol.2002;22: 3174-3177.","DOI":"10.1128\/MCB.22.9.3174-3177.2002"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/2\/572\/1699723\/zh801404000572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/2\/572\/1699723\/zh801404000572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:49:51Z","timestamp":1682660991000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/2\/572\/18336\/Bone-marrow-transplantation-restores-immune-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,15]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-12-4226","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,15]]}}}